key: cord-0939689-tt7w4m71 authors: Zama, Daniele; Pancaldi, Livia; Baccelli, Francesco; Guida, Fiorentina; Gottardi, Francesca; Dentale, Nicola; Esposito, Fabio; Masetti, Riccardo; Viale, Pierluigi; Pession, Andrea title: Autoimmune hemolytic anemia in children with COVID‐19 date: 2021-09-07 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29330 sha: 70646091e1f4727f6b2db7a27b5e1185c363a2d2 doc_id: 939689 cord_uid: tt7w4m71 nan To the Editor, Pediatric 2019 novel coronavirus disease (COVID-19) is characterized by a wide clinical spectrum, including hematological manifestations. 1 Anemia and thrombocytopenia occur mainly in severe forms of the disease and in multisystem inflammatory syndrome 2 but are rare in asymptomatic and mildly symptomatic patients. Only few reports of autoimmune hemolytic anemia (AIHA), rarely associated with immune thrombocytopenia (ITP), have been described in children with COVID-19. [3] [4] [5] Here, we present two pediatric cases of severe cold agglutinin disease and a brief review of the literature. AIHA is a rare disorder in children, often secondary to self-limited viral or bacterial infections. 6 When treatment is required, corticosteroids represent the first-line therapy. Other options include rituximab and IVIG. 7 This condition is more common in children with innate or acquired immune dysregulation (e.g., autoimmune lymphoproliferative syndrome, post-HSCT), in whom the management is frequently challenging. 8 Moreover, AIHA can be combined with thrombocytopenia (Evans syndrome). 7 Since the beginning of the pandemic, AIHA has seldom been described in adults with COVID-19 9,10 and appears to be even rarer in children. [3] [4] [5] The five pediatric patients reported in literature so far (see Table S1 ) developed severe anemia during the acute phase of infection (hemoglobin range 2.3-6.3 g/dl). No child presented with symptoms of severe respiratory syndrome. They all received steroids as first-line therapy, while only one child required rituximab, because of refractory course of disease. 4 According to our clinical practice in ES, IVIG were administered as second-line treatment. 11 All patients showed a clinical response within 1 month. One child was previously affected by refractory chronic ITP. 3 Our second patient developed AIHA 6 months after allogeneic HSCT, during CsA therapy. The other three patients had no relevant comorbidities. In our first case, immunological investigations excluded underlying immune disorders. Severe AIHA has to be considered within the spectrum of pediatric COVID-19 complications. ITP and bilinear cytopenia (Evans syndrome) can also be associated with SARS-Cov2, even if rarely reported in the pediatric population so far. 3, 4, [12] [13] [14] [15] The underlying pathogenic mechanism could be related to the predominant immunological and inflammatory activation secondary to SARS-CoV-2 infection. 1, 2, 16 Furthermore, in adults immune-mediated cytopenia seems to be more common in the moderate-to-severe respiratory form of COVID-19. 16 On the contrary, affected children did not present any respiratory involvement. Molecular mimicry has also been proposed as potential mechanism for ITP. 16 Indeed, Angileri et al. reported the structural affinity and potential cross-reactivity between erythrocyte membrane protein Ankyrin-1 and viral protein spike. 17 The severity of anemia appears not to be dependent on the patient's The authors declare that there is no conflict of interest. Hematological manifestations of SARS-CoV-2 in children COVID-19 and multisystem inflammatory syndrome in children and adolescents COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation SARS-CoV-2 infection in two pediatric patients with immune cytopenias: a single institution experience during the pandemic. Pediatr Blood Cancer Autoimmune hemolytic anemia in a pediatric patient with severe acute respiratory syndrome coronavirus 2 infection Autoimmune hemolytic anemia: current knowledge and perspectives Autoimmune hemolytic anemia in children: mayo clinic experience Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies Autoimmune haemolytic anaemia associated with COVID-19 infection COVID-19-associated immune thrombocytopenia Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia Immune thrombocytopenia secondary to COVID-19 infection: report of two cases Severe pediatric COVID-19 presenting with respiratory failure and severe thrombocytopenia Immune thrombocytopenia (ITP) in a pediatric patient positive for SARS-CoV-2 Evans syndrome in a patient with COVID-19 Immune thrombocytopenia secondary to COVID-19: a systematic review Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19?